(Lung Cancer) Ramucirumab Drug Information
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Ramucirumab (Cyramza), an anti-angiogenic drug for non-small cell lung cancer, officially approved in Japan
On June 20, Japan's Eli Lilly announced that the anti-angiogenic VEGFR2 antibody Ramucirumab (Cyramza) had received manufacturing and marketing approval for the treatment of unresectable, recurrent non-small cell lung cancer (NSCLC).
The approval was based on multiple study results, including: international multi-center, placebo-controlled, double-blind, randomized Phase III clinical trial (REVEL trial); Japan-specific multi-center, placebo-controlled, double-blind, randomized Phase II clinical trial (JVCG trial); and other supporting evidence.
In the REVEL trial, the study population included patients with NSCLC who were currently receiving or had progressed or relapsed after platinum-based chemotherapy. The trial compared placebo + docetaxel versus Ramucirumab + docetaxel as second-line chemotherapy in patients with progressive or relapsed NSCLC. Results showed improved overall survival with the combination compared to chemotherapy alone.
The JVCG trial enrolled Stage IV NSCLC patients (with or without maintenance therapy) who were receiving or had received first-line platinum-based chemotherapy. The trial was limited to Japanese patients and compared placebo + docetaxel versus Ramucirumab + docetaxel for efficacy. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival and response rate. Results showed consistent trends with the REVEL trial.
Note: Docetaxel is the European taxane (known in Taiwan as Taxotere).
Reference: A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4